Keywords: Shire, Vyvanse, ADHA, Maintenance of efficacy, Children
Efficacy of Shire's Vyvanse maintained in ADHD adolescents after at least six months
Article | 24 May 2012
A significantly lower proportion of subjects experiencing treatment failure whilst receiving UK specialty drugmaker Shire’s (LSE: SHP) attention-deficit ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
